Laboratory for Personalized Medicine

Prof. Galina I. Lifshits

D.Med.Sci.
Phone: +7 383 363 01 87,
Email

• Study of role of genetic predisposition and pathophysiological mechanisms in development of metabolic syndrome, obesity, diabetes.
• Complex study of gene association of hemostasis system with predisposition to atherothrombosis.
• Development of method of personalized selection of indirect anticoagulants and antiagregant doses in patients with venous and arterial thromboses after cardiac interventions.
• Development of method of personalized selection of antihipertensia therapy in patients with cardiovascular diseases.
• Development of method of personalized selection of antihyperglycemic therapy in patients with type 2 diabetes.
• Development and introduction of new progressive methods of gene diagnostic and treatment of non-malignant and malignant diseases of a thyroid gland.

• Program of genetic testing of patients to detect predisposition to development of cardiovascular diseases, osteoporosis, disturbances of reproductive function, oncological diseases – “Genetic map of health” was improved and introduced in practice.
• Original program complex “Genetics” - database of clinical and molecular-genetic information - is developed and introduced in practice.
• Evidences of role of genetic violations in development of trombofilia are obtained.
• Associations of polymorphic variants of metabolism genes of indirect anticoagulants with warfarin concentration and its metabolites in plasma at patients and healthy volunteers are revealed.
• Associations of genes of clopidogrel metabolism with sensitivity to antiplatelet therapy in patients after cardiac interventions are revealed.
• Genes changes, which contribute to obesity and type 2 diabetes, are revealed.
• Associations between genetic markers and sensitivity to antihyperglycemic therapy at patients with type 2 diabetes are revealed.
• Association of exhaled air composition with early metabolic violations at patients of high risk of development of type 2 diabetes is revealed.

1. Os'kina N.A., Boyarskikh U.A., Lazarev A.F., Petrova V.D., Ganov D.I., Tonacheva O.G., Lifshits G.I., Filipenko M.L. A replication study examining association of rs6983267, rs10090154, and rs1447295 common single nucleotide polymorphisms in 8q24 region with prostate cancer in Siberians. Urol. Onkol. 2014. 32(1), 37.e7–37.e12.
2. Koh N.V., Lifshits G.I. Value of pharmacogenetic studies for a personalized approach to pharmacotherapy with statins. Bulletin ESSC SB RAMS. 2013. 5, 176-181.
3. Os’kina N.A., Ermolenko N.A., Boyarskikh U.A., Lazsrev A.F., Petrova V.D., Ganov D.I., Kunin I.S., Tonacheva O.G., Lifshits G.I., Filipenko M.L., Investigation of the association of single nucleotide polymorphisms in genes substitutions of antioxidant enzymes with the risk of prostate cancer in the Siberian region of Russia. Siberian oncological journal. 2013. Suppl. 3, 37-42.
4. Knauer N.Y., Lifshits G.I., Voronina E.N., Koleda N.V., Gus’kova E.V. Informativeness of genetic factors for optimization of personalized therapy with clopidogrel. Cardiology. 2013. 53(8), 72-75.
5. Knauer N.Y., Lifshits G.I., Voronina E.N. Laboratory evaluation of the effectiveness of clopidogrel therapy in patients with cardiovascular disease and its association with molecular genetic parameters. Science in contemporary informational society. 2013. 1, 27-30.
6. Oskina N.А., Boyarskikh U.А., Lazarev А.F., Petrova V.D., Ganov D.I., Tonacheva О.G., Lifshits G.I., Filipenko М.L. The chromosomal region 8q24 is associated with increased risk of prostate cancer in the Siberian region of Russia, a meta-analysis. Molecular Biology (Moscow). 2012. 46(2), 234.
7. Tsvetovskaya G.A., Chikova E.D. Koch N.V., Lifshits G.I. Morozov V.V., Novikova Y.V. Modern methods of laboratory diagnostics in prevention of repeated thromboses. Fundamental research. 2012. 10-2, 353-355.
8. Surovtseva M.N., Sokolova E.A., Voronina E.N., Pronin S.V., Filipenko M.L. Association of the 54-nucleotide repeat polymorphism of hPer3 with opioid dependence in residents of the West Siberian region. Psychiatr. Genet. 2012. 22(6), 309-310.
9. Belozertseva L.A., Voronina E.N., Kokh N.V., Tsvetovskaya G.A., Momot A.P., Lifshits G.I., Filipenko M.L., Shevela A.I., Vlassov V.V. Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? The Epma J. 2012. 3(1), 10.
10. Khvostov M.V., Tolstikova T.G., Chernonosov A.A., Fedorova O.S., Lifshits G.I. Pharmacokinetic alterations of warfarin in its clathrate with arabinogalactan. Asian Journal of Pharmaceutical and Clinical Research. 2012. 5(4), 251-252.
11. Nikolaev K.Yu., Nikolaeva A.A., Popova L.V., Ovsiannikova А.K., Lifshits G.I., Gicheva I.М. Pathogenesis of development of chronic renal disease at arterial hypertension. SB RAMS Bulletin. 2012. 32(5), 48-54.
12. Nechepurenko I.V., Boyarskikh U.A., Komarova N.I., Polovinka M.P., Filipenko M.L., Lifshits G.I., Salakhutdinov N.F., Tolstikov G.A. LDLR Up-Regulatory Activity of Berberine and Its Bromo and Iodo Derivatives in Human Liver HepG2 Cells. Doklady Chemistry. 2011. 439, 204-208.
13. Lifshits G. I., Danilkina S. T., Guskova E.V., Voronina E.N., Filipenko M. L. Association of the genes coding proteins of a hemostasis, with parameters of a peripheri hemostasis and predisposition to atherothrombosis at patients with cardiovascular diseases. Cardiovascular therapy and prevention. 2011. 4, 90-96.
14. Tolstikova T.G., Khvostov M.V., Lifshits G.I., Dushkin A.V., Meteleva E.S. Alteration of Warfarin’s Pharmacologic Properties in Clathrates with Glycyrrhizic Acid and Arabinogalactan. Letters in Drug Design & Discovery. 2011. 8(3), 201-204.
15. Kudryavtseva E.A., Rozhdestvenskii A.S., Kakulya A.V., Khanokh E.V., Delov R.A., Malkova N.A., Korobko D.S., Platonov F.A., Aref'eva E.G., Zagorskaya N.N., Aliferova V.M., Titova M.A., Babenko S.A., Smagina I.V., El'chaninova S.A., Zolovkina A.G., Lifshits G.I., Puzyrev V.P., Filipenkо M.L. Polymorphic locus rs10492972 of t.he KIF1B gene association with multiple sclerosis in Russia: case control study. Molecular Genetics and Metabolism. 2011. 104(3), 390-394.

Partner integration project of the Presidium of SB RAS (2012-2014)

• N.91 “Informativity assessment of genetic markers of human diseases in the Russian population identified by GWA analysis, and development of new approaches to increase of efficiency of their identification”

Program of the Presidium of RAS (2013-2015)
N.5 “Basic Science for Medicine”

• N.20 “Translational researches of pharmacogenetic technologies in therapy of cardiovascular diseases”.